Literature DB >> 27048161

Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma.

P Jiménez-Fonseca1, J M Gómez Saez2, J Santamaria Sandi3, J Capdevila4, E Navarro Gonzalez5, C Zafon Llopis6, T Ramón Y Cajal Asensio7, G Riesco-Eizaguirre8, E Grande9, J C Galofré10.   

Abstract

Anaplastic thyroid cancer (ATC) is the most aggressive solid tumor and almost uniformly lethal in humans. The Boards of the Thyroid Cancer Group of the Spanish Society of Endocrinology and Nutrition and the Grupo Español de Enfermedades Huérfanas e Infrecuentes of the Spanish Society of Oncology requested that an independent task force draft a more comprehensive consensus statement regarding ATC. All relevant literature was reviewed, including serial PubMed searches together with additional articles. This is the first, comprehensive Spanish consensus statement for ATC and includes the characteristics, diagnosis, initial evaluation, treatment goals, recommendations and modalities for locoregional and advanced disease, palliative care options, surveillance, and long-term monitoring. Newer systemic therapies are being investigated, but more effective combinations are needed to improve patient outcomes. Though more aggressive radiotherapy has reduced locoregional recurrences, median overall survival has not improved in more than 50 years.

Entities:  

Keywords:  Anaplastic thyroid carcinoma; Distant metastases; Genetic abnormalities; Poorly differentiated thyroid carcinoma

Mesh:

Year:  2016        PMID: 27048161     DOI: 10.1007/s12094-016-1506-0

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  58 in total

1.  Anaplastic Thyroid Carcinoma, Version 2.2015.

Authors:  Robert I Haddad; William M Lydiatt; Douglas W Ball; Naifa Lamki Busaidy; David Byrd; Glenda Callender; Paxton Dickson; Quan-Yang Duh; Hormoz Ehya; Megan Haymart; Carl Hoh; Jason P Hunt; Andrei Iagaru; Fouad Kandeel; Peter Kopp; Dominick M Lamonica; Judith C McCaffrey; Jeffrey F Moley; Lee Parks; Christopher D Raeburn; John A Ridge; Matthew D Ringel; Randall P Scheri; Jatin P Shah; Robert C Smallridge; Cord Sturgeon; Thomas N Wang; Lori J Wirth; Karin G Hoffmann; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2015-09       Impact factor: 11.908

2.  Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways.

Authors:  Dingxie Liu; Mingzhao Xing
Journal:  Thyroid       Date:  2008-08       Impact factor: 6.568

3.  BRAF V600E inhibition in anaplastic thyroid cancer.

Authors:  Michael H Rosove; Parvin F Peddi; John A Glaspy
Journal:  N Engl J Med       Date:  2013-02-14       Impact factor: 91.245

4.  Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review.

Authors:  Eric J Sherman; Su Hsien Lim; Alan L Ho; Ronald A Ghossein; Matthew G Fury; Ashok R Shaha; Michael Rivera; Oscar Lin; Suzanne Wolden; Nancy Y Lee; David G Pfister
Journal:  Radiother Oncol       Date:  2011-10-06       Impact factor: 6.280

5.  Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information.

Authors:  C Montero-Conde; J M Martín-Campos; E Lerma; G Gimenez; J L Martínez-Guitarte; N Combalía; D Montaner; X Matías-Guiu; J Dopazo; A de Leiva; M Robledo; D Mauricio
Journal:  Oncogene       Date:  2007-09-17       Impact factor: 9.867

6.  Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib.

Authors:  Thomas Hogan; H James Williams; Ramin Altaha
Journal:  J Oncol Pharm Pract       Date:  2009-03-10       Impact factor: 1.809

Review 7.  Anaplastic thyroid cancer: prevalence, diagnosis and treatment.

Authors:  S Chiacchio; A Lorenzoni; G Boni; D Rubello; R Elisei; G Mariani
Journal:  Minerva Endocrinol       Date:  2008-12       Impact factor: 2.184

Review 8.  Molecular diagnostics and predictors in thyroid cancer.

Authors:  Marina N Nikiforova; Yuri E Nikiforov
Journal:  Thyroid       Date:  2009-12       Impact factor: 6.568

9.  Multiple pluripotent stem cell markers in human anaplastic thyroid cancer: the putative upstream role of SOX2.

Authors:  Valeria Carina; Giovanni Zito; Giuseppe Pizzolanti; Pierina Richiusa; Angela Criscimanna; Vito Rodolico; Laura Tomasello; Maria Pitrone; Walter Arancio; Carla Giordano
Journal:  Thyroid       Date:  2013-06-21       Impact factor: 6.568

10.  A significant response to sunitinib in a patient with anaplastic thyroid carcinoma.

Authors:  Enrique Grande; Jaume Capdevila; Juan José Díez; Federico Longo; Alfredo Carrato
Journal:  J Res Med Sci       Date:  2013-07       Impact factor: 1.852

View more
  3 in total

Review 1.  The emerging function and clinical significance of circRNAs in Thyroid Cancer and Autoimmune Thyroid Diseases.

Authors:  Yu Zhang; Dong-Dong Jia; Yi-Fei Zhang; Meng-Die Cheng; Wen-Xiu Zhu; Pei-Feng Li; Yin-Feng Zhang
Journal:  Int J Biol Sci       Date:  2021-04-17       Impact factor: 6.580

2.  Circular RNA EIF6 (Hsa_circ_0060060) sponges miR-144-3p to promote the cisplatin-resistance of human thyroid carcinoma cells by autophagy regulation.

Authors:  Feng Liu; Jin Zhang; Long Qin; Ziyao Yang; Jianxia Xiong; Yanyan Zhang; Ruihuan Li; Shujing Li; Huifang Wang; Bo Yu; Wenjun Zhao; Weiran Wang; Zhensu Li; Jing Liu
Journal:  Aging (Albany NY)       Date:  2018-12-12       Impact factor: 5.682

Review 3.  Anaplastic Thyroid Carcinoma: An Update.

Authors:  Arnaud Jannin; Alexandre Escande; Abir Al Ghuzlan; Pierre Blanchard; Dana Hartl; Benjamin Chevalier; Frédéric Deschamps; Livia Lamartina; Ludovic Lacroix; Corinne Dupuy; Eric Baudin; Christine Do Cao; Julien Hadoux
Journal:  Cancers (Basel)       Date:  2022-02-19       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.